Clinical Trials Browser

Phase 2 × Acetylcarnitine × Genitourinary × Clear all

NCT00751205 2014-10-28

Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)

Phase 2 Completed

GenitourinaryGynecologic

Ovarian Neoplasms, Peripheral Nervous System Diseases, Prostatic Neoplasms